In this article (Mol Can Ther 2014 April; 13:867–79), which was published in the April 2014 issue of Molecular Cancer Therapeutics (1), the authors regret that dosing is incorrectly stated as “3 times a day” in the legend for Figure 6 and in the xenograft section of the Materials and Methods. The correct dosing is “every three days.” In addition, the authors acknowledge that the titles of the xenograft models in Fig. 6 incorrectly read as “PDX” followed by a number. They should instead be titled “ST” followed by the number.
Birinapant exhibits single-agent activity in patient-derived xenograft models of ovarian and colorectal cancer, and melanoma at a well-tolerated dose. Birinapant activity was shown in low passage, patient-derived xenograft models of ovarian cancer (A), colorectal cancer (B), and melanoma (C). Vehicle control (
) or birinapant (30 mg/kg; 
) was dosed intraperitoneally once every 3 days as indicated (↑).
The authors would like to acknowledge South Texas Accelerated Research
Therapeutics (START) for performing the in vivo studies.
- ©2014 American Association for Cancer Research.
Volume 13, Issue 9
